Alpha Tau Medical Ltd. Warrant closed at $4.10 on Sep 28, up 4.59%, 6.2% below its highest close since Mar 8. Volume of 16.9K shares was 0.30× its 20-day average (below normal).
Split-adjusted performance: +2.5% over one month, +368.6% over six months.
Short interest was 4.0K shares at the Sep 15 settlement, down 24.6% from the prior report (1.0 days to cover).
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range.
What is DRTSW's market cap?
$95.98M, based on the Sep 28 close of $4.10.
About Alpha Tau Medical Ltd. Warrant
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
